August 29th 2021
Experts discussed data from trials in lymphoma presented at ASCO 2021.
July 31st 2021
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed novel treatment options for patients with hematologic malignancies.
July 29th 2021
The professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma.
July 28th 2021
Stephen J. Schuster, MD, discussed tisagenlecleucel's efficacy and safety over other available treatments for relapsed/refractory FL.
July 19th 2021
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.
July 9th 2021
The director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute discussed overall response rate and stringent complete responses in the CARTITUDE-1 trial.
July 8th 2021
The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed how the meeting sets the foundation for what’s to come in the treatment of multiple myeloma and other hematologic malignancies.
June 27th 2021
The recommendation comes after positive data was released from the recent phase 2 KarMMa trial.
June 26th 2021
Philippe Moreau, MD, discussed the CARTITUDE-1 trial's promising results with ciltacabtagene autoleucel read out at the 2021 ASCO Annual Meeting.